S
S. Cohen
Publications - 4
Citations - 993
S. Cohen is an academic researcher. The author has contributed to research in topics: Placebo & Bone density. The author has an hindex of 2, co-authored 3 publications receiving 948 citations.
Papers
More filters
Journal ArticleDOI
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
TL;DR: The daily, but not cumulative, GC dose was found to be a strong predictor of vertebral fracture in patients receiving oral glucocorticoids, and postmenopausal women taking GCs, as compared with nonusers of GCs had considerably higher risks of fracture.
Journal ArticleDOI
Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy
Stanley Wallach,S. Cohen,David M. Reid,R.A. Hughes,David J. Hosking,Roland Laan,S. M. Doherty,Michael Maricic,Clifford J. Rosen,Janet E. Brown,I P Barton,Chines Arkadi Aaron +11 more
TL;DR: Risedronate was efficacious in both men and women, irrespective of underlying disease and duration of corticosteroid therapy, and had a favorable safety profile, with a similar incidence of upper gastrointestinal adverse events in the placebo and active treatment groups.
Journal Article
Predictors for vertebral fracture and fracture threshold in patients using oral corticosteroids.
Journal ArticleDOI
Ab0511 a phase 1, randomised, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety, pharmacokinetics and pharmacodynamics of pf-06835375 in patients with seropositive systemic lupus erythematosus or rheumatoid arthritis
S. Cohen,Jean S. Beebe,Vishala Chindalore,Shanhong Guan,Mina Hassan-Zahraee,Claire Hyde,Rebeka Levin,Shannon Lubaczewski,M.P. Salganik,A. J. Sloan,Eva Stevens,Elena Peeva,Michael S. Vincent,David Martinez,Myron Chu +14 more
TL;DR: PF-06835375 is a humanised, afucosyl IgG1 antibody selective against C-X-C chemokine receptor type 5 (CXCR5) as discussed by the authors .